Therapeutic inhibition of RAS in non-small cell lung cancer
Oncogenic KRAS mutations are the most common driver event in NSCLC, occurring in up to 30% of patients. Direct strategies to target KRAS (and other RAS isoforms) met with consistent failure until the discovery of covalent KRAS G12C inhibitors, leading to a first-in-class FDA accelerated approval for...
Na minha lista:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2026-06-01
|
| coleção: | Frontiers in Oncology |
| Assuntos: | |
| Acesso em linha: | https://www.frontiersin.org/articles/10.3389/fonc.2026.1817943/full |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|